- Oral presentation
- Open Access
Diffuse myocardial fibrosis - a therapeutic target? Proof of regression at 1-year following aortic valve replacement: the RELIEF-AS study
Journal of Cardiovascular Magnetic Resonance volume 18, Article number: O37 (2016)
In aortic stenosis (AS), LVH occurs due to cellular hypertrophy and extracellular matrix expansion (diffuse fibrosis). After aortic valve replacement (AVR) early regression has been shown by extracellular volume fraction (ECV) measurement to be cellular regression at 6 months, but diffuse fibrosis regression, predicted by one year, has not been demonstrated non-invasively. Myocardial fibrosis is a key potential drug target for new therapies in heart failure, and non-invasive proof of fibrosis regression would be a major proof-of-concept milestone in validating this target, with CMR a key candidate technique to quantify change. We used CMR ECV measurement to track the change in cell and fibrosis volume following AVR (RELIEF-AS Study: NCT 02174471).
123 patients with symptomatic, severe AS (AVAi 0.4 ± 0.1 cm2/m2) underwent CMR at 1.5T prior to AVR. 95 patients attended repeat CMR 1-year post-op (age 69 ± 11 years; 56% male); 5 declined, 10 patients died and 13 had pacemakers implanted. T1 mapping (ShMOLLI) was performed prior to and at 15 minutes post-contrast (Dotarem). Global ECV was derived from 3 short axis T1 maps excluding segments with infarct-pattern LGE. Fibrosis volume (LV mass * ECV) and cell volume (LV mass * [1-ECV]) were calculated.
After AVR, LV mass regressed by 20% (171 ± 63 g to 136 ± 42 g, p < 0.001, Figure 1). Unexpectedly, ECV increased (28.7 ± 2.6% to 30.3 ± 3.2%, p < 0.001), which was the result of a 17% reduction in fibrosis volume (48 ± 19 ml to 40 ± 13 ml, p < 0.001) and a (higher) 23% reduction in cell volume (117 ± 42 ml to 90 ± 28 ml, p < 0.001, Figure 2). Native myocardial T1 was unchanged (975 ± 34 ms vs 971 ± 31 ms, p = 0.6). Mean baseline NT-pro-BNP levels declined from 174 pmol/L [IQR 29-214] to 98 pmol/L [IQR 23-126] (p = 0.01). Fibrosis volume reduction correlated well with NT-pro-BNP reduction (R2 = 0.44, p < 0.001).
We show for the first time non-invasively that myocardial fibrosis regresses at 1-year following AVR - but less than cellular regression, so there is a small rise in ECV post AVR. These data support the position that human diffuse fibrosis is dynamic and that this is measurable by CMR - a key biological result and proof-of-concept for drug development targeting myocardial fibrosis.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Treibel, T.A., Fontana, M., Kozor, R. et al. Diffuse myocardial fibrosis - a therapeutic target? Proof of regression at 1-year following aortic valve replacement: the RELIEF-AS study. J Cardiovasc Magn Reson 18 (Suppl 1), O37 (2016). https://doi.org/10.1186/1532-429X-18-S1-O37
- Aortic Stenosis
- Aortic Valve Replacement
- Myocardial Fibrosis
- Potential Drug Target
- Matrix Expansion